TECHNOLOGY

Renatus is developing next-generation cholesterol modulators with superior therapeutic efficacy and enhanced patient safety through its proprietary cyclodextrin technology.

First-Generation Cholesterol Modulator

One of the most well-known cyclodextrins, hydroxypropylated beta cyclodextrin (HPβCD), has been explored as a first-generation cholesterol modulator in clinical development for diseases including Alzheimer’s disease, atherosclerosis, and Niemann–Pick type C.

The Challenge: The Limitations of HPβCD

Although HPβCD was discovered more than three decades ago and carries several well-recognized limitations, it has remained the primary option due to its cholesterol-modulating properties and the absence of more precise alternatives.

CMC(Chemistry, Manufucaturing, and Controls) & Quality Challenges: As a random mixture of countless isomers, HPβCD struggles with batch-to-batch inconsistency, making it difficult to ensure a uniform quality profile and predictable pharmacokinetics.
High Dosage Burden: Due to its low cholesterol-solubilizing capacity, HPβCD requires excessively high dosages to be effective, which increases the risk of dose-related side effects.

The Renatus Breakthrough: Single Isomer Technology

Renatus has moved beyond the "random mix" approach. We have successfully engineered innovative Single Isomer Cyclodextrins, a next-generation solution that redefines efficacy and safety.

High Purity: Unlike conventional mixtures, our technology is based on a single, pure molecular structure, engineered through a defined and controlled synthesis rather than random functionalization, as seen with HPβCD. This leads to highly predictable and consistent results.

Heterogenous mixture and single isomer 2.png

Superior Solubilization: Our single isomer design is engineered for maximum "grip" on cholesterol. It exhibits significantly higher cholesterol-solubilizing capacity compared to HPβCD.

Lower Dose, Higher Impact: Because our molecules are more efficient at capturing cholesterol, we can achieve better therapeutic results with lower, safer dosages.